



M K PROTEINS

Date: 12.08.2025

*To  
The Manager  
Listing Compliance  
Bombay Stock Exchange Limited  
P.J.Towers, Dalal Street,  
Mumbai-400 001  
Maharashtra, India  
SCRIP CODE: 543919*

*To  
The Manager  
Listing Compliance  
National Stock Exchange of India  
Limited (NSE)  
Exchange Plaza, Bandra Kurla Complex,  
Bandra East, Mumbai - 400051  
NSE SYMBOL: MKPL*

**Subject: Outcome of Board Meeting held today i.e. on 12<sup>th</sup> August 2025**

Dear Sir/Madam,

With reference to the above, we hereby submit / inform that:

1. The Board of Directors (“the Board”) of the Company at its meeting held today i.e. on 12<sup>th</sup> August, 2025, approved the Un-Audited Financial Results of the Company for the quarter ended 30<sup>th</sup> June, 2025. The said Un-Audited Financial Results prepared in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 together with the Limited Review Report (LRR) are enclosed. These results are also being uploaded on the Company’s website at [www.mkproteins.in](http://www.mkproteins.in).
2. M/s. KRA & Co., Statutory Auditors (FRN: 020266N), vide letter dated 5<sup>th</sup> August, 2025 have tendered their resignation as Statutory Auditors of the Company, effective from the closure of business hours of 12<sup>th</sup> August 2025 which has been intimated to Stock Exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015 vide Company letter dated 5<sup>th</sup> August 2025.

**The Audit Committee and the Board of Directors of the Company noted that the existing Statutory Auditors have not raised any concern or issue for their resignation and there is no reason other than as stated in their resignation letter dated 5<sup>th</sup> August, 2025.**

**This disclosure is made in compliance of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024.**

3. Pursuant to the provisions of Section 139 (8) of the Companies Act, 2013 read with the rules framed thereunder and on the recommendation of the Audit Committee, the Board has approved, subject to the approval of shareholders within a period of three

---

## **M. K. Proteins Limited**

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: [www.mkproteins.in](http://www.mkproteins.in) | E: [compliancemkproteins@gmail.com](mailto:compliancemkproteins@gmail.com)

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



## M K PROTEINS

months, the appointment of M/s. Subhash Sajal & Associates, Chartered Accountants, (FRN: 018178N) as Statutory Auditors of the Company to fill the casual vacancy caused due to resignation of M/s. KRA & Co., Chartered Accountants (FRN: 020266N), and to hold the office till the conclusion of ensuing 13<sup>th</sup> Annual General Meeting of the Company to be held for financial year ended 31st March, 2025.

The disclosure required pursuant to Regulation 30 of SEBI (LODR) Regulations read with Part A of Para A of Schedule III to the said Regulations and also as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 with regard to appointment of M/s Subhash Sajal & Associates Chartered Accountants as Statutory Auditors is enclosed herewith as "Annexure -A".

4. Based on recommendation of the Audit Committee, approved the appointment of M/s. J.P. Jagdev & Co., Peer Reviewed Firm of Practising Company Secretaries, (M. No: 2469, C.P. 2056) Secretarial Auditors of the Company to conduct Secretarial Audit for a period of 5 (five) years commencing from financial year 2025-26 till financial year 2029-30, subject to approval of the members of the Company at the ensuing AGM.

The details as required under SEBI Listing Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 is enclosed herewith as "Annexure -B".

The Meeting commenced at 3:30 P.M. and concluded at 4:30 P.M.

Thanking you,

Yours Truly,

**For M K Proteins Limited**

**Neha Aggarwal**

**Company Secretary cum Compliance Officer**

---

## M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W : www.mkproteins.in | E : compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



M K PROTEINS

**Annexure A**

**Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024.**

**Details of Statutory Auditor**

S. No.	Particulars	Statutory Auditor
		M/s. Subhash Sajal & Associates
1.	<b>Reason for change viz. appointment, resignation, removal, death or otherwise;</b>	Appointment
2.	<b>Date of appointment/cessation (as applicable) &amp; term of appointment;</b>	Date of Appointment: 12/08/2025  Reason and Term of Appointment: To fill the casual vacancy in the office of Statutory Auditors due to resignation of M/s. KRA & Co., Chartered Accountants, Statutory Auditors of the Company.  M/s. Subhash Sajal & Associates, Chartered Accountants shall hold office till the conclusion of 13 <sup>th</sup> Annual General Meeting of the Company.
3.	<b>Brief Profile (in case of appointment)</b>	M/s. Subhash Sajal & Associates, (FRN: 018178N) Office Address: 1766, New Christian Colony, Near Civil Hospital, Jagadhri-135003  M/s Subhash Sajal & Associates (FRN 018178N) is a professionally managed Chartered Accountancy firm based out of Haryana that specializes in statutory audits, tax, financial compliance, and advisory for a diverse set of clients. The firm is well recognized in the industry and listed as statutory auditor for various listed and unlisted companies. Their experienced team handles a spectrum of compliance and reporting services in line with Indian regulatory requirements. The Board and the Audit Committee looked into the above mentioned factors while making their appointment in casual vacancy.
4.	<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	NA

---

## **M. K. Proteins Limited**

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



M K PROTEINS

**Annexure-B**

**Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024.**

**Details of Secretarial Auditor**

<b>S. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Reason for change viz. appointment, <del>resignation, removal,</del> or otherwise	Appointment: M/s. J.P. Jagdev & Co., Company Secretaries, appointed as the Secretarial Auditor of the Company.
2.	Date of appointment/ <del>cessation</del> & term of appointment	Term of 5 (Five) years commencing from Financial Year 2025-26 till Financial Year 2029-30 subject to the approval of Members in ensuing Annual General Meeting.
3.	Brief Profile (in case of appointment)	<p>Name of Secretarial Auditor: M/s. J.P. Jagdev &amp; Co, Company Secretaries</p> <p>Email id: jpjncoin@gmail.com</p> <p>Office Address: 22-A, Kanshi Nager, Model Town, Ambala City-134003 HR</p> <p>Field of Experience: Mr. Jai Prakash Jagdev is a Company Secretary (M. No. 2469 &amp; COP No. 2056), based in Ambala. He has vast experience in the field of Company Law, Secretarial Work, Due Diligence, SEBI Regulations etc.</p> <p>While recommending M/s. J.P. Jagdev &amp; Co, Company Secretaries for appointment, the Board and the Audit Committee evaluated various factors, including his experience, its industry standing, the clientele it serves, and its technical expertise. His firm has been Peer Reviewed by the Institute of Company Secretaries of India (ICSI), ensuring the highest standards in professional practices.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director).	NA

---

## **M. K. Proteins Limited**

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



# K R A & C O.

**Chartered Accountants**

☎ 011 - 47082855  
Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034



**Limited Review Report on Standalone Quarterly and year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**

To,  
The Board of Directors,  
M. K. Proteins Limited

1. We have reviewed the accompanying statement of unaudited quarterly standalone financial results of **M. K. Proteins Limited** ("the Company") for the quarter ended June 30, 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (hereafter referred to as "the Regulations"), to the Stock Exchange.
2. The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, interim financial reporting (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Results are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited quarterly Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI( Listing Obligations and Disclosure Requirements) Regulations,2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi  
Date: 12<sup>th</sup> August 2025

For KRA & Co.,  
Chartered Accountants  
Firm Registration No. 020266N

**RAJAT GOYAL**  
(PARTNER)  
Membership No.: 503150  
UDIN: 25503150BMJCHT2397

## M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE 2025

(Rs. In Lacs)

	QUARTER ENDED			YEAR ENDED	
	30-06-2025 (UNAUDITED)	31-03-2025 (AUDITED)	30-06-2024 (UNAUDITED)	31-03-2025 (AUDITED)	31-03-2024 (AUDITED)
<b>1. Revenue</b>					
a) Revenue from Operations (Net)	11494.60	13720.41	5733.30	26770.60	24557.11
b) Other Income	0.00	1.94	0.00	47.66	44.66
Sub-Total "1"	11494.60	13722.35	5733.30	26818.26	24601.77
<b>2. Expenditure</b>					
a) Cost of Material Consumed	8770.74	11229.32	2559.25	16674.36	20571.80
b) Purchase of Stock-in-Trade	1688.76	2343.13	407.96	5149.41	3294.36
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	146.31	(1176.68)	2156.91	2146.27	(2223.11)
d) Employees Benefits Expenses	53.70	82.49	65.78	274.52	278.80
e) Manufacturing, Operating and Other Expenses	284.07	776.29	169.46	1282.93	973.61
f) Finance Costs	70.16	67.44	32.82	110.50	106.49
g) Depreciation and Amortization Expenses	10.35	8.85	7.41	35.17	52.85
Sub-Total "2"	11024.09	13330.84	5399.59	25673.16	23054.80
<b>3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [ 1 - 2 ]</b>	470.51	391.51	333.71	1145.10	1546.97
<b>4 Exceptional Items</b>	0.00	0.00	0.00	0.00	0.00
<b>5 Profit/(Loss) before Extraordinary items and Tax [ 3 - 4 ]</b>	470.51	391.51	333.71	1145.10	1546.97
<b>6 Extraordinary Items</b>	0.00	0.00	0.00	0.00	0.00
<b>7 Profit/(Loss) before Tax [ 5 - 6 ]</b>	470.51	391.51	333.71	1145.10	1546.97
<b>8 Tax Expenses</b>					
a) Provision for Current Tax	118.15	111.54	84.49	301.86	417.73
b) Provision for Deferred Tax Liability/(Adjustment)	1.04	0.36	1.09	3.50	8.05
c) Prior Year Taxes	0.00	0.00	0.00	0.00	0.00
Sub-Total "8"	119.19	111.90	85.58	305.36	425.78
<b>9 Profit/(Loss) for the Period from continuing operations [ 7 - 8 ]</b>	351.32	279.61	248.13	839.74	1121.19
<b>10 Profit/(Loss) for the period from Discontinuing operations before tax</b>	0.00	0.00	0.00	0.00	0.00
<b>11 Tax expenses of Discontinuing operations</b>	0.00	0.00	0.00	0.00	0.00
<b>12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11]</b>	0.00	0.00	0.00	0.00	0.00
<b>13 Profit/(Loss) for the Period [ 9 + 12 ]</b>	351.32	279.61	248.13	839.74	1121.19
<b>14 Other Comprehensive Income net of taxes</b>					
a) (i) Amount of items that will not be reclassified to profit and loss	0.00	(1.51)	0.00	(1.51)	(0.55)
(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	(0.38)	0.00	(0.38)	(0.14)
b) (i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
Sub- Total "14"	0.00	(1.13)	0.00	(1.13)	(0.41)
<b>15 Total comprehensive Income for the Period [13 + 14]</b>	351.32	278.48	248.13	838.61	1120.78



19

<b>16</b>	<b>Earnings per share (refer Note 7)</b>					
a)	Earnings per Equity Share for continuing operations					
	Basic earnings/(Loss) per share from continuing operations	0.09	0.07	0.07	0.22	0.30
	Diluted earning/(Loss) per share from continuing operation:	0.09	0.07	0.07	0.22	0.30
b)	Earnings per Equity Share for discontinuing operations					
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share					
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.09	0.07	0.07	0.22	0.30
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.09	0.07	0.07	0.22	0.30
<b>17</b>	<b>Details of Equity Share Capital</b>					
	Paid-up Equity Share Capital	3753.72	3753.72	3753.72	3753.72	3753.72
	Face value of Equity Share Capital	1	1	1	1	1
<b>18</b>	<b>Other Equity [Reserves]</b>	-	-	-	3192.86	2353.84

**Note:**

1. The above mentioned un-audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12<sup>th</sup> August, 2025.
2. Previous period/year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
4. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations & Disclosure Requirements, 2015).

Place: Ambala

Dated: 12/08/2025

For and on behalf of the board



(Parmod Kumar)  
Managing Director  
DIN: 00126965